These findings suggest that SPE may offer a promising adjunctive therapeutic approach for glaucoma by targeting IOP-independent mechanisms, including the modulation of oxidative stress, inflammation, and neurotrophic support [157]
Compounding BPC-157: A regulatory loophole In a statement, Health Canada said "BPC157 has not been authorized, its safety, efficacy, and quality have not been assessed and there is limited scientific evidence to support its use, including a lack of established human dosing protocols." In addition, the regulator says BPC-157 is not approved for use in any NHPs in any form, including oral and injectable, but it can still be compounded for topical use or oral administration as an NHP
The dosage is typically adjusted based on the patients response and tolerance to the medication
If weight gain continues, consult a healthcare provider
How Zepbound Works: A Dual-Action Approach Zepbounds efficacy stems from its unique dual-agonist mechanism, mimicking two naturally occurring gut hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)
For breastfeeding mothers, the wait continues until complete weaning plus an additional stabilization period
